[Risedronate for treatment of osteoporosis].
Risedronate is effective and approved for the treatment of osteoporosis in Japan. Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts. Risedronate was shown to significantly decrease the risk of nonvertebral fractures including hip fractures as well as vertebral fractures in placebo-controlled, 3-year clinical trials in postmenopausal women with osteoporosis. The efficacy of risedronate elucidated by recent clinical studies was reviewed.
Hagino
Hiroshi
H
School of Health Science, Faculty of Medicine, Tottori University.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid